Market Overview

UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential

Share:
Related XOMA
Morning Market Gainers
Benzinga's Top #PreMarket Gainers
XOMA: Phase 3 EYEGUARD-B Trial Is Good News For Gevokizumab (Seeking Alpha)

Credit Suisse initiated coverage on XOMA Corporation (NASDAQ: XOMA) with an Outperform rating and a $4 price target.

Credit Suisse commented, "Xoma has recently refocused its efforts and bolstered its balance sheet to advance the development of gevokizumab for multiple indications. Retained marketing rights, a well-designed clinical program, and multiple data readouts in the next 12 months provide for upside potential, although with speculative risk."

XOMA Corporation closed at $2.67 on Monday.

Latest Ratings for XOMA

DateFirmActionFromTo
May 2015Credit SuisseAssumesNeutral
Mar 2015Ladenburg ThalmannUpgradesNeutralBuy
Nov 2014Ladenburg ThalmannDowngradesBuyNeutral

View More Analyst Ratings for XOMA
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (XOMA)

Around the Web, We're Loving...